Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Derry, Christopher J ^a   Derry, Sheena ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUMATRIPTAN; SEROTONIN 1 AGONIST;

ACUTE DISEASE; ADULT; ADVERSE EVENT; ANALGESIA; COMPARATIVE STUDY; DATA EXTRACTION; DATA SYNTHESIS; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MEDICATION COMPLIANCE; MIGRAINE; PAIN SEVERITY; PLACEBO EFFECT; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; LITERATURE; META ANALYSIS; MIGRAINE DISORDERS; NUMBERS NEEDED TO TREAT; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; DRUG ADMINISTRATION ROUTES; HUMANS; MIGRAINE DISORDERS; NUMBERS NEEDED TO TREAT; REVIEW LITERATURE AS TOPIC; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 84922520119     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009108.pub2     Document Type: Review

References (51)

1. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008615].
2. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009665].
3. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009663].
4. Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009664].
5. Ayzenberg I, Katsarava Z, Sborowski A, Chernysh M, Osipova V, Tabeeva G, et al.The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 2012;32(5):373-81. [DOI: 10.1177/0333102412438977].
6. Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 2003;23(7):487-90.
7. Bigal ME, Bordini CA, Antoniazzi AL, Speciali JG. The triptan formulations: a critical evaluation. Arquivos de Neuro-Psiquiatria 2003;61(2A):313-20.
8. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559-66. [DOI: 10.1212/01.wn1.0000323925.29520.e7].
9. Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, et al.Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain 2012;13(5):361-78. [DOI: 10.1007/s10194-012-0460-7].
10. British National Formulary. http://www.medicinescomplete.com/mc/bnf/current/PHP2854-sumatriptan.htm (Accessed 30 October 2013). London: BMJ Group and Pharmaceutical Press, 2013; Vol. October.
11. Brandes JL, Cady RK, Freitag FG, Smith TR, Chandler P, Fox AW, et al.Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49(10):1435-44.
12. Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, et al.Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2012;52(1):3-17. [DOI: 10.1111/j.1526-4610.2011.02046.x].
13. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
14. de Craen AJ, Tijssen JG, de Gans J, Kleijnen J. Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. Journal of Neurology 2000;247(3):183-8.
15. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63. [DOI: 10.1111/j.1526-4610.2006.00631.x].
16. Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia 2008;28(10):1003-11.
17. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58. [DOI: 10.1046/j.1468-2982.2002.00404.x].
18. Gendolla A. Early treatment in migraine: how strong is the current evidence?. Cephalalgia 2008;28(Suppl 2):28-35.
19. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends in Molecular Medicine 2007;13(1):39-44. [DOI: 10.1016/j.molmed.2006.11.005].
20. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health 2009;12(1):55-64. [DOI: 10.1111/j.1524-4733.2008.00404.x].
21. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20(9):765-86.
22. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33(9):629-808. [DOI: 10.1177/0333102413485658].
23. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010;70(12):1505-18. [DOI: 10.2165/11537990-000000000-00000].
24. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD008541.pub2].
25. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). Journal of Headache and Pain 2005;6(6):429-40. [DOI: 10.1007/s10194-005-0252-4].
26. Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barré J, Katsarava Z, et al.The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology 2012;19(5):703-11. [DOI: 10.1111/j.1468-1331.2011.03612.x].
27. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 1999;39(Suppl 2):S20-S26.
28. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, AMPP Advisory Group, et al.Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9.
29. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46(5):715-25. [DOI: 10.1111/j.1526-4610.2006.00430.x].
30. Macedo A, Farré M, Baños JE. A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials. European Journal of Clinical Pharmacology 2006;62(3):161-72.
31. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002915].
32. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16.
33. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5].
34. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: Examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9.
35. Moore RA, Derry CJ, Derry S, Straube S, McQuay HJ. A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. European Journal of Pain 2012;16(4):585-91. [DOI: 10.1016/j.ejpain.2011.08.009].
36. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148].
37. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al.Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009;49(4):498-508. [DOI: 10.1111/j.1526-4610.2009.01369.x].
38. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al.Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515].
39. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-57.
40. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002;42 Suppl 1:10-7. [DOI: 10.1046/j.1526-4610.2002.0420s1010.x].
41. Prescribing and Primary Care team, Health and Social Care Information Centre. Prescription cost analysis, England 2012. http://data.gov.uk/dataset/prescription_cost_analysis_england [Accessed 17 Apr 2013]. Government Statistical Service: Health and Social Care Information Centre, 2013. [ISBN: 978-1-84-636859-2].
42. Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009;49(6):817-25.
43. Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache 2009;49(1):79-89. [DOI: 10.1111/j.1526-4610.2008.01263.x].
44. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al.Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;7:10. [DOI: 10.1186/1471-2288-7-10].
45. Steiner TS, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Journal of Headache and Pain 2013;14:1. [DOI: 10.1186/1129-2377-14-1].
46. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain 2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0].
47. Tfelt-Hansen P, Pascual J, Ramadan N, Dahlöf C, D'Amico D, Diener HC, et al.Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 2012;32(1):6-38. [DOI: 10.1177/0333102411417901].
48. Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. Journal of Clinical Epidemiology 2000;53(2):207-16. [DOI: 10.1016/S0895-4356(99)00161-4].
49. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30(9):1065-72. [DOI: 10.1177/0333102409355601].
50. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al.Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 1016/S0140-6736(12)61729-2].
51. Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J, et al.The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 2012;52(4):582-91. [DOI: 10.1111/j.1526-4610.2011.02061.x].